# Advisor Review - Advisor 1/3

**Role:** Academic advisor checking for fatal errors
**Model:** gpt-5.2-2025-12-11
**Paper:** paper.pdf
**Reasoning effort:** high
**Timestamp:** 2026-01-28T15:35:24.940198
**Response ID:** resp_0e707c47fc562e6600697a1e28cd808194b41e77be359f4311
**Tokens:** 6241 in / 4474 out
**Response SHA256:** 057b8ad7890a887c

---

## Checklist Review for Fatal Errors (pre-submission)

### 1) Data–Design Alignment (CRITICAL)
- **Treatment timing vs. data coverage:** You study staggered adoption **2012–2019** with outcome data **2011–2019**. This is internally feasible: max(treatment year) = 2019 ≤ max(data year) = 2019. No fatal mismatch.
- **Post-treatment observations by cohort:** Each adoption cohort has at least one post-treatment year in-sample (for the **2019 cohort**, post-treatment is only **t = 2019**). This is not a misalignment (though it implies limited dynamics for late cohorts). Not fatal.
- **Always-treated handling:** You correctly state that **pre-2012 adopters are always-treated** given outcomes start in 2011 and thus do not contribute to identification under Callaway–Sant’Anna. This is consistent across the abstract, intro, and tables. No fatal inconsistency detected.
- **Treatment definition consistency:** Treatment is defined as “law in effect for the full calendar year.” Tables and narrative consistently refer to adoption cohorts 2012–2019 for identification. No internal contradiction found.

### 2) Regression Sanity (CRITICAL)
Checked **Tables 2–5** and the reported main estimates:
- **Implausible coefficients:** None. Main ATT is −0.48 percentage points; cohort effects as large as −3.61 pp are plausible given the outcome mean (~19%).
- **Implausible SEs / collinearity symptoms:** None. SEs are not enormous; no cases where SE is wildly larger than the coefficient in a way suggesting a broken regression output.
- **Impossible values (NaN/Inf/negative SE/R² outside [0,1]):** None shown.

### 3) Completeness (CRITICAL)
- **Placeholders (TBD/NA/XXX):** None.
- **Regression tables report N and uncertainty:** Table 3 reports **SE, CI, p-value, N**; Table 5 reports **SE, p-value, N**. This meets the “not unfinished” threshold.
- **Figures/tables referenced but missing:** In the provided draft text, **Figure 1 and Tables 1–5 are present and referenced consistently.** No “see Table X” with missing objects detected.
- **Methods described but results absent:** Event study is described and a figure is provided; robustness checks described and Table 5 is provided. No fatal omissions.

### 4) Internal Consistency (CRITICAL)
- **Numbers match across abstract/text/tables:**  
  - Abstract ATT **−0.48 (SE 0.35), CI [−1.16, 0.20]** matches **Table 3**.  
  - Counts are consistent: Table 1 implies **16 + 11 = 27** adopters in 2012–2019, matching Table 3.  
  - Total jurisdictions: **10 always-treated + 27 treated cohorts + 14 never-treated = 51**, consistent throughout.
- **Timing/sample period consistency:** All reported analyses use **2011–2019**. No conflicting sample windows detected.

ADVISOR VERDICT: PASS